LDS/Medical Tests/Zopiclone, Urine

Zopiclone, Urine

Zopiclone is a cyclopyrrolone derivative that is used to treat insomnia, in a manner similar to zolpidem. Although zopiclone is not a benzodiazepine drug, it is typically considered to be benzodiazepine-like. For example, like the benzodiazepine class of drugs, zopiclone exerts its activity through interaction with the GABAA receptor. Likewise, the benzodiazepine antagonist flumazenil may be used to reverse symptoms of zopiclone overdose. However, zopiclone does not exhibit the anxiolytic or anticonvulsant properties of benzodiazepine drugs, unless used in extremely high doses. The typical route of administration is oral. The dextrorotatory stereoisomer of zopiclone is available as a drug called eszopiclone. The half-life of immediate release zopiclone is 3.5–6.5 hours. Zopiclone is metabolized to N-oxide and N-desmethyl metabolites that are eliminated in the urine. A single dose is typically eliminated within 24 hours. Common side effects: headache, daytime drowsiness, amnesia, dizziness, ataxia, confusion, hostility, irritability, and vivid or disturbing dreams. Overdose effects include shallow respiration, deep sedation, clammy skin, dilated pupils, weak and rapid pulse, coma, and possible death.
  • Adherence monitoring
  • Drug abuse evaluation
  • Toxicity/Overdose assessment
A qualitative positive result indicates only the presence of Zopiclone and does not necessarily correlate with the extent of physiological and psychological effects nor does it predict the dose that was taken or administered. Any result that is inconsistent with clinical expectations should be confirmed or quantitated by a second method. An unexpected negative result could reflect inadequate specimen handling.

Therapeutic levels: 0.01-0.1 mg/L Toxic levels: Data not available *Note: therapeutic ranges and toxic thresholds are best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration are preferred for pharmacokinetic analyses.* **Cut-Off Ranges** Cut-off values are used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection, or laboratory, or whether the test is a qualitative method or a quantitative method. The testing laboratory cut-off range is listed on the patient report.

Liquid Chromatography/Mass Spectroscopy (LC/MS, LC-MS/MS), Gas Chromatography/Mass Spectroscopy (GC/MS), or Thin Layer Chromatography (TLC). Immunoassays (IA) for zopiclone are not available.

Fresh urine specimen (random) collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Creatinine or specific gravity results will identify dilute specimens. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4*, *CYP3A5*, *CYP2D6*, *CYP2C9*, and *CYP2C19* variants could guide drug and dose selection. Supportive testing such as liver profile, kidney profile, comprehensive metabolic panel, CBC (if overdose), and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 9th ed. Seal Beach, CA: Biomedical Publications; 2011.
  • Brunton LL, Chabner B, Knollman B (eds). Goodman and Gilmans’ the pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill; 2010.
  • Katzung BG, Masters S, Trevor AK (eds). Basic and clinical pharmacology, 12th ed. New York: McGraw-Hill; 2011.